Tin tức & Cập nhật
Lọc theo Chuyên ngành:

SC vs IV pembrolizumab: Which route is better for metastatic NSCLC?
30 Apr 2025
bởiStephen Padilla
In patients with treatment-naive metastatic nonsmall cell lung cancer (NSCLC), subcutaneous (SC) pembrolizumab (pembro) demonstrates comparable efficacy to that of intravenous (IV) pembro as regards overall exposure and trough concentration, reports a study presented at ELCC 2025.
SC vs IV pembrolizumab: Which route is better for metastatic NSCLC?
30 Apr 2025
Neoadjuvant chemo plus durvalumab improves survival in NSCLC
30 Apr 2025
bởiStephen Padilla
The addition of durvalumab to neoadjuvant chemotherapy with cisplatin and docetaxel results in better survival rates among patients with resectable nonsmall cell lung cancer (NSCLC), according to a study presented at ELCC 2025.